Damora Therapeutics, Inc. DMRA

Rank #2272 · Nasdaq · $1.3B market cap

⚠ Going-concern flag — the auditor (EY Godkendt Revisionspartnerselskab) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

26.5

P/E

-61.7

P/B

40.91

ROE

-66.3%

Op. Margin

–%

Debt Ratio

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -61.7x, P/B 40.91x. Ranks in the top 81% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -66.3%. Ranks in the top 91% of the universe.

Safety ★★★★★

Excellent

Debt ratio 4%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	$0.0B	$-0.0B	$-0.0B	–	-24
2021	–	$-0.0B	$-0.0B	$-0.1B	–	-9
2022	–	$-0.1B	$-0.1B	$0.2B	–	3
2023	–	$-0.1B	$-0.1B	$0.1B	–	10
2024	–	$-0.0B	$-0.0B	$0.1B	–	10
2025	–	$-0.0B	$-0.0B	$0.0B	–	4

← See the full screener